Portola Pharmaceuticals Inc (PTLA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

270 EAST GRAND AVENUE, SUITE 22 SOUTH SAN FRANCISCO, CA 94080

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboemboli® prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery.

Data as of 2019-12-02 22:27:29 -0500
Market Cap2.18 Billion Shares Outstanding76.359 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-4.148
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low37.95 / 14.81 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from PTLA instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PTLA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PTLA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RENTON HOLLINGS

  • Director
No longer subject to file 2020-07-02 0

WOLFF HENRY WARD

  • Director
No longer subject to file 2020-07-02 0

BIRD JEFFREY W

  • Director
0 2020-07-02 0

DIER MARDI EVP AND CFO

  • Officer
No longer subject to file 2020-07-02 0

BREGE LAURA

  • Director
No longer subject to file 2020-07-02 0

FENTON DENNIS M

  • Director
No longer subject to file 2020-07-02 0

JOHNSON JOHN

  • Director
No longer subject to file 2020-07-02 0

STUMP DAVID C

  • Director
No longer subject to file 2020-07-02 0

MORIARTY JOHN B EVP, GENERAL COUNSEL

  • Officer
No longer subject to file 2020-07-02 0

BRAME GLENN P EVP, CTOO

  • Officer
No longer subject to file 2020-07-02 0

MEYER ERNIE EVP AND CHRO

  • Officer
No longer subject to file 2020-07-02 0

GARLAND J. SCOTT PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2020-07-02 0

KOENIG SHELDON L. EVP, CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2020-07-02 0

LOVE TED W

  • Director
No longer subject to file 2020-07-02 0

PATNI RAJIV EVP, CMO

  • Officer
No longer subject to file 2020-07-02 0

CURNUTTE JOHN T EVP R&D

  • Officer
No longer subject to file 2019-05-17 0

HOMCY CHARLES J

  • FORMER DIRECTOR
No longer subject to file 2019-03-28 0

FU TAO EVP, CBO

  • Officer
77,043 2018-08-31 0

LIS WILLIAM CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
204,448 2018-07-28 0

LAWRENCE JOHN H III SVP, CHIEF MEDICAL OFFICER

  • Officer
6,875 2018-01-31 0

MAXWELL (MAURITIUS) PTE LTD

CAIRNHILL INVESTMENTS (MAURITIUS) PTE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
No longer subject to file 2017-06-01 0

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
6,583,568 2015-12-09 0

CALIFF ROBERT

  • Director
0 2014-06-27 0

GALAKATOS NICHOLAS

  • Director
0 2014-06-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Index Plus All-Cap Fund PTLA -1.0 shares, $-7.13 2020-03-31 N-PORT

Elevate your investments